Author(s)

José M. García-Mediero¹, Francisco Sánchez-Ballester², Daniel Arumi³, Isabel Lizarraga^4*

¹Department of Urology, Hospital MD Anderson, Madrid, Spain.
²Department of Urology, Hospital General Universitario de Valencia, Valencia, Spain.
³Medical Department, Pfizer Inc. Europe, Alcobendas (Madrid), Spain.
⁴Medical Unit, Pfizer, S.L.U., Alcobendas (Madrid), Spain.

Aim: To explore in daily clinical practice the evolution in time of the fesoterodine and solifenacin dose pattern and assess the therapeutic benefit provided by the highest dose of these anti-muscarinics. Patients and Methods: This was a post-hoc analysis of data from an observational, cross-sectional, retrospective and multicenter study. Adult patients diagnosed with over active bladder (OAB) who initiated fesoterodine or solifenacin treatment were included. Data on the prescribed treatment and dose, change of dose, reasons for switching and treatment benefit were recorded. Results: A total of 828 subjects were analyzed (262 receiving solifenacin and 566 fesoterodine). Most subjects were women with a mean time since diagnosis of more than one year and aged around 60 years old. The majority of patients initiated the OAB treatment with the lowest available dose (64% fesoterodine vs. 77% solifenacin). At the follow-up visit 54% of the fesoterodine group and 66% of the solifenacin opted for dose escalation. At the study visit, 70.1% fesoterodine vs. 43.3% solifenacin remained on the highest dose. A significantly greater proportion of subjects receiving fesoterodine 8 mg, reported higher improvement in terms of both patient-reported-treatment benefit and clinical global impression compared with solifenacin 10 mg (p < 0.05). Conclusion: In routine clinical practice more than half of the patients opted for the higher dose and remained on it over time, suggesting a desire for greater efficacy. Fesoterodine 8 mg seems to provide greater benefits from the physician’s and the patient’s point of view compared with those provided by solifenacin 10 mg.

Fesoterodine, Flexible-Dose, Overactive Bladder, Solifenacin

García-Mediero, J. , Sánchez-Ballester, F. , Arumi, D. and Lizarraga, I. (2016) Dose Pattern Evolution and Therapeutic Benefit in Patients on Solifenacin or Fesoterodine Treatment in Daily Clinical Practice. Open Journal of Urology, 6, 91-101. doi: 10.4236/oju.2016.66017.